Priapism at the onset of acute lymphoblastic leukemia in a 12-year-old child
- Authors: Inyoshina A.D.1, Kapustina А.S.1, Smirnova А.Y.1, Grin Е.А.2, Baratashvili G.G.1, Kagantsov I.М.1, Dinikina Y.V.1
-
Affiliations:
- The Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation
- Center for Endoscopic Urology and New Technologies at the St. Luke Clinical Hospital
- Issue: Vol 23, No 1 (2024)
- Pages: 139-145
- Section: CLINICAL OBSERVATIONS
- Submitted: 15.03.2023
- Accepted: 27.03.2023
- Published: 27.03.2023
- URL: https://hemoncim.com/jour/article/view/708
- DOI: https://doi.org/10.24287/1726-1708-2024-23-1-139-145
- ID: 708
Cite item
Full Text
Abstract
Acute lymphoblastic leukemia (ALL) is the most common cancer in the clinical practice of pediatric oncology/hematology. At the onset of the disease, patients can develop such a life-threatening complication as hyperleukocytosis with leukostasis that can manifest in many different ways, including ischemic priapism, an extremely rare type of leukostasis in children with ALL. Apart from death associated with hyperleukocytosis caused by the underlying disease, inadequate and poorly timed specific therapy and supportive care can lead to erectile dysfunction, impotence or intermittent priapism in the future. In this article, we report an extremely rare clinical case of ischemic priapism in a 12-year-old patient that developed at the onset of ALL and was the only manifestation of the disease as well as the reason for admission to hospital. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications. Here, we analyzed special aspects of this complication, described modern treatment strategies and provided an international literature review. We emphasize the importance of urgent care delivery due to the critical prognostic significance of timely and adequate treatment provided by a multidisciplinary team.
About the authors
A. D. Inyoshina
The Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation
Email: alisaineshinansk@gmail.com
ORCID iD: 0000-0001-7794-9095
Saint Petersburg
Russian FederationА. S. Kapustina
The Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation
Email: kapustina-annna@yandex.ru
ORCID iD: 0000-0002-6758-1546
Saint Petersburg
Russian FederationА. Yu. Smirnova
The Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation
Email: misha12_09@mail.ru
ORCID iD: 0000-0002-5293-9568
Saint Petersburg
Russian FederationЕ. А. Grin
Center for Endoscopic Urology and New Technologies at the St. Luke Clinical Hospital
Email: sv.lukaendouro@gmail.com
ORCID iD: 0000-0002-8685-6525
Saint Petersburg
Russian FederationG. G. Baratashvili
The Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation
Email: barat777@mail.ru
Saint Petersburg
Russian FederationI. М. Kagantsov
The Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation
Email: ilkagan@rambler.ru
ORCID iD: 0000-0002-3957-1615
Saint Petersburg
Russian FederationYu. V. Dinikina
The Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation
Author for correspondence.
Email: dinikina_yuv@almazovcentre.ru
ORCID iD: 0000-0002-2003-0982
Yulia V. Dinikina, Cand. Med. Sci., Head of the Department
Department of Chemotherapy for Cancer and Hematologic Diseases and Bone Marrow Transplantation in Children
197341; 2 Akkuratova St., St. Petersburg
Russian FederationReferences
- Hunger S.P., Mullighan C.G. Acute lymphoblastic leukemia in children. N Engl J Med 2015; 373 (16): 1541–52. doi: 10.1056/NEJMra1400972
- Pshonkin A.V., Rumyantseva Yu.V., Litvinov D.V., Karelin A.F., Boychenko E.G., Lagoyko S.N., et al. Treatment of acute lymphoblastic leukemia in adolescents and young adults: the experience of the Moscow–Berlin. Russian Journal of Pediatric Hematology and Oncology 2016; 3 (1): 35–43. doi: 10.17650/2311-1267-2016-3-1-35-43 (In Russ.)
- Ganzel C., Becker J., Mintz P.D., Lazarus H.M., Rowe J.M. Hyper-leukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 2012; 26 (3): 117–22. doi: 10.1016/j.blre.2012.01.003
- Pham H.P., Schwartz J. How we approach a patient with symptoms of leukostasis requiring emergent leukocytapheresis. Transfusion 2015; 55 (10): 2306–11. doi: 10.1111/trf.13210
- Stahl M., Shallis R.M., Wei W., Montesinos P., Lengline E., Neukirchen J., et al. Management of hyper-leukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia 2020; 34 (12): 3149–60. doi: 10.1038/s41375-020-0783-3
- Spring J., Munshi L. Oncologic Emergencies: Traditional and Contemporary. Crit Care Clin 2021; 37 (1): 85–103. doi: 10.1016/j.ccc.2020.08.004
- Zuckerman T., Ganzel C., Tallman M.S., Rowe J.M. How I treat hematologic emergencies in adults with acute leukemia. Blood 2012; 120 (10): 1993–2002. doi: 10.1182/blood-2012-04-424440
- Korkmaz S. The management of hyperleukocytosis in 2017: Do we still need leukapheresis? Transfus Apher Sci 2018; 57 (1): 4–7. doi: 10.1016/j.transci.2018.02.006
- Porcu P., Cripe L.D., Ng E.W., Bhatia S., Danielson C.M., Orazi A., McCarthy L.J. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000; 39 (1–2): 1–18. doi: 10.3109/10428190009053534
- Lichtman M.A., Rowe J.M. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood 1982; 60 (2): 279–83.
- Stucki A., Rivier A.S., Gikic M., Monai N., Schapira M., Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001; 97 (7): 2121–9. doi: 10.1182/blood.v97.7.2121
- Ganzel C., Becker J., Mintz P.D., Lazarus H.M., Rowe J.M. Hyper-leukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 2012; 26 (3): 117–22. doi: 10.1016/j.blre.2012.01.003
- Montague D.K., Jarow J., Broderick G.A., Dmochowski R.R., Heaton J.P., Lue T.F., et al. American Urological Association guideline on the management of priapism. J Urol 2003; 170 (4 Pt 1): 1318–24. doi: 10.1097/01.ju.0000087608.07371.ca
- Broderick G.A., Kadioglu A., Bivalacqua T.J., Ghanem H., Nehra A., Shamloul R. Priapism: pathogenesis, epidemiology, and management. J Sex Med 2010; 7 (1 Pt 2): 476–500. doi: 10.1111/j.1743-6109.2009.01625.x
- Rodgers R., Latif Z., Copland M. How I manage priapism in chronic myeloid leukaemia patients. Br J Haematol 2012; 158 (2): 155–64. doi: 10.1111/j.1365-2141.2012.09151.x
- Vilke G.M., Harrigan R.A., Ufberg J.W., Chan T.C. Emergency evaluation and treatment of priapism. J Emerg Med 2004; 26 (3): 325–9. doi: 10.1016/j.jemermed.2003.12.011
- Mulhall J.P., Honig S.C. Priapism: etiology and management. Acad Emerg Med 1996; 3 (8): 810–6. doi: 10.1111/j.1553-2712.1996.tb03520.x
- Donaldson J.F., Rees R.W., Steinbrecher H.A. Priapism in children : a comprehensive review and clinical guideline. J Pediatr Urol 2014; 10 (1): 11–24. doi: 10.1016/j.jpurol.2013.07.024
- Gokce A., Gul D., Orhan M.F., Büyükavci M., Demir G., Beyaz S.G. Epidural blockade for alternative management of priapism: A case report of child with T-cell acute lymphoblastic leukemia. Urology 2021; 156: e121–3. doi: 10.1016/j.urology.2021.06.017
- Vadakan V.V., Ortega J. Priapism in acute lymphoblastic leukemia. Cancer 1972; 30 (2): 373–75. doi: 10.1002/1097-0142(197208)30:2<373::aid-cncr2820300211>3.0.co;2-g
- van der Velde M.G.A.M., Tiellemans S.M..B, de Lil H., Nieuwenhuizen L. The value of leukapheresis for treatment of priapism as presenting feature of chronic myeloid leukemia-Case report and review of literature. EJHaem 2022; 3 (4): 1100–15. doi: 10.1002/jha2.545
- Röllig C., Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood 2015; 125 (21): 3246–52. doi: 10.1182/blood-2014-10-551507
- Ruggiero A., Rizzo D., Amato M., Riccardi R. Management of Hyper-leukocytosis. Curr Treat Options Oncol 2016; 17 (2): 7. doi: 10.1007/s11864-015-0387-8
- Ganzel C., Becker J., Mintz P.D., Lazarus H.M., Rowe J.M. Hyper-leukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 2012; 26 (3): 117–22. doi: 10.1016/j.blre.2012.01.003
- Levey H.R., Segal R.L., Bivalacqua T.J. Management of priapism: an update for clinicians. Ther Adv Urol 2014; 6 (6): 230–44. doi: 10.1177/1756287214542096
- Burnett A.L., Sharlip I.D. Standard operating procedures for priapism. J Sex Med 2013; 10 (1): 180–94. doi: 10.1111/j.1743-6109.2012.02707.x
- Capece M., Falcone M., Cai T., Palmieri A., Cocci A., La Rocca R. Penile Prosthesis Implantation in Refractory Ischaemic Priapism: Patient Selection and Special Considerations. Res Rep Urol 2022; 14: 1–6. doi: 10.2147/RRU.S278807
- Reddy A.G., Alzweri L.M., Gabrielson A.T., Leinwand G., Hellstrom W.J.G. Role of Penile Prosthesis in Priapism: A Review. World J Mens Health 2018; 36 (1): 4–14. doi: 10.5534/wjmh.17040
Supplementary files
